Big Pharma Conversion from Legacy Revenue Management to Innovative ICyte SaaS Platform

IntegriChain was approached by a top-15 pharma manufacturer with 39 in-line therapies covering 73 indications and an additional 12 drugs in phase 3 clinical trials. Most recently, their legacy portfolio is facing significant public policy pressure. Additionally, their overall portfolio has changed with planned launches of next-generation, self-administered specialty drugs which target smaller patient populations, are high-priced, and will face increased payer policy restrictions and require aggressive commercial payer contracting. This case study highlights how IntegriChain delivered their innovative ICyte Saas Platform to help the manufacturer identify and resolve obstacles. Download below!